INSIGHTS INTO US LEGISLATION

10 July 1994

The probability of a health care reform bill drops significantly if there is no agreement in principle by the July 4 recess, White House Office of Legislative Affairs director Patrick Griffin told a recent Lehman Brothers health care conference in Washington DC. Agreement in principle can mean many things, such as the outlines of a bipartisan deal in the Senate Finance Committee.

And it was probably with this in mind that agreement was reached by this Committee over the weekend ahead of July 4 (see facing page). What is interesting is that although several of the Committee members expressed varying degrees of dissatisfaction with the bill's proposals, most voted for it because that was the only way to get it to the floor of the Senate.

Also speaking at the Lehman conference was Hillary Rodham Clinton, who rejected market forces as a sufficient means of continuing the reduction in health care inflation should reform efforts cease, and vigorously criticized possible soft or hard "trigger" prohibition in legislation, and other compromises.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight